Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Year of progress against key objectives; On track for ambitious growth path

SpiroChem
Posted on: 05 Mar 18

Basel, Switzerland, March 5th, 2018. SpiroChem AG (“SpiroChem” or the “Company”), the Swiss Fine Chemicals company providing bespoke chemistry services to support drug discovery in the life sciences industry, today announces its Annual Summary for 2017.

 

  • Relocated to state-of-the-art laboratories in Basel, Switzerland
  • Closed financing round of over 1 mioCHF
  • Strengthened Board of Directors with hiring of Dr. Anthony Baxter

 

Dr. Thomas C. Fessard, CEO of SpiroChem, said: “2017 has been an important year for SpiroChem as we transitioned from an early stage company to quickly becoming a key partner of the Life Sciences industry for complex medicinal chemistry.

 

“With a growing demand for our products and services, we relocated our company from Zürich to state-of-the-art laboratories in Basel in order to provide the infrastructure for our rapidly-growing business. To support this growth, we have raised funds, extended our team of highly talented and motivated chemists, and notably, appointed Dr. Anthony Baxter to our Board of Directors. 

 

We have seen increased interactions with all sectors of life sciences (pharma, biotech, academia) and chemistry, leading to a revenue growth of over 40% and 36% new customers (in comparison with FY 2016). We are also benefiting from growing referrals from existing customers and partners, thus expanding our reach beyond the usual business development activities. This is a sign of maturity for SpiroChem and is a testament to the tangible added value we bring to our customers.

 

This traction is also indicative of our increasingly strong market position. Pharma is eager to fill the widening gap of competence resulting from shrinking internal resources and the overdependence upon low-cost CROs. The industry realizes that new partners must be found to deliver ever-more-challenging chemistry and chemical innovation. At SpiroChem we offer our customers premium scientific services which will be a cornerstone of their drug discovery processes of tomorrow.

 

But premium services alone are not sufficient to grow our business and meet our vision of SpiroChem as the leading chemical innovation provider to the industry. SpiroChem also works in partnership with our clients to craft novel solutions for the complex chemistry challenges they face. Through internal R&D and fruitful collaborations with leading academic groups, we are developing new classes of molecules, processes, methodologies and concepts to support the thirst for innovation in the Life Science industry. A pipeline of new products and services will be disclosed and offered to our clients in the coming year.

 

“In 2018, our strategy is to focus on organic growth, targeting larger deals with key new and existing customers across the industry, which we believe will reinforce and build our reputation as the partner of choice for externalization of complex, IP-sensitive or time-critical chemistry projects.

 

For additional information, please visit: https://spirochem.com/news

 

SpiroChem’s CEO, Dr. Fessard, will be participating in the The Medicinal Chemistry Roundtable Discussions Strategy Meeting on the 6th of March at the Radisson Blu Hotel in Zürich, Switzerland.

 

 

Contacts

 

SpiroChem AG

Tel:  +41 61 685 95 00

Thomas Fessard, CEO

 

 

 

FTI Consulting

Tel:  +44 20 3727 1000

Mo Noonan / Sam Purewal

 

 

Notes to Editors

 

SpiroChem AG is a Swiss Fine Chemical Company founded in 2011 as an ETH-Zürich spin-off (group of Prof. Erick Carreira).  SpiroChem has established itself as a world-leader in the field of novel building blocks for drug discovery and the expert on bioisosteric switch strategies. The Company has a broad portfolio of clients across the biotech and pharmaceutical industry as well as world-leading fine chemical companies.

 

SpiroChem drives the new molecule and synthesis innovation process, leading the way to new classes of molecules with highly attractive cost/benefit profiles due their intrinsic properties: 1) improved physico-chemical and pharmaco-kinetic properties and 2) chemical novelty allowing the generation of new intellectual property. The beneficial properties of SpiroChem’s compounds mean that our clients can optimize their drug candidates faster, therefore accelerating their drug discovery programs.

 

With recognized excellence in drug design and proprietary process chemistry technologies, SpiroChem efforts have been recognized with several entrepreneurial awards.  It is the recipient of two sizable Swiss government grants (KTI).  The forward-thinking initiatives enable discovery and innovation within the framework of research collaborations with ETH-Zürich. 

 

Visit the website https://spirochem.com/ and explore a new world of possibilities for innovation and discovery.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 05/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.